Abstract-Essential hypertension is a complex disease affected by genetic and environmental factors and serves as a major risk factor for cardiovascular diseases. Serum lysophosphatidic acid correlates with an elevated blood pressure in rats, and lysophosphatidic acid interacts with 6 subtypes of receptors. In this study, we assessed the genetic association of lysophosphatidic acid receptors with essential hypertension by genotyping 28 single-nucleotide polymorphisms from genes encoding for lysophosphatidic acid receptors, LPAR1, LPAR2, LPAR3, LPAR4, LPAR5, and LPAR6 and their flanking sequences, in 3 Han Chinese cohorts consisting of 2630 patients and 3171 controls in total. We identified a single-nucleotide polymorphism, rs531003 in the 3′-flanking genomic region of LPAR1, associated with hypertension (the Bonferroni corrected P=1.09×10 -5 , odds ratio [95% confidence interval]=1.23 [1.13-1.33]). The risk allele C of rs531003 is associated with the increased expression of LPAR1 and the susceptibility of hypertension, particularly in those with a shortage of sleep (P=4.73×10 -5 , odds ratio [95% confidence interval]=1. 75 [1.34-2.28]). We further demonstrated that blood pressure elevation caused by sleep deprivation and phenylephrine-induced vasoconstriction was both diminished in LPAR1-deficient mice. Together, we show that LPAR1 is a novel susceptibility gene for human essential hypertension and that stress, such as shortage of sleep, increases the susceptibility of patients with risk allele to essential hypertension. 
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E
ssential hypertension (EH) is a complex disease influenced by genetic and environmental factors. It is a major risk factor for cardiovascular diseases, stroke, and end-stage renal disease. [1] [2] [3] [4] Despite of huge efforts made over the past decades and >50 genes and loci identified associated with EH and blood pressure by genome-wide association study (GWAS; Table S1 in the online-only Data Supplement), searches for genes or chromosomal loci that are linked to EH by population-based genetic approaches remain problematic. The challenges with finding EH genes may be because of population stratification, genetic heterogeneity of EH, and effects from confounding factors. Therefore, there is a need to combine genetic analysis with functional characterization to identify a causative gene for EH.
In addition to genetic factors, several lines of evidence suggest a contribution of stress to the genesis of EH. Mental stress induces nervousness, anxiety, irritability, and other emotions lead to an increased serum epinephrine and blood pressure. 5 Shortage of sleep has been demonstrated to be associated with elevated blood pressure as well. 6 Compared with normal sleep duration, restricted sleep is associated with an increase in both systolic blood pressure (SBP) and diastolic blood pressure. [7] [8] [9] However, few studies have discussed the influences of genetic factors on EH associated with such stresses. Lysophosphatidic acid (LPA) is a small lipid molecule that interacts with G protein-coupled LPA receptors 1 to 6 (LPAR1-6), which mediate a variety of cellular responses, such as proliferation, survival, cytoskeletal changes, and calcium influx. [10] [11] [12] [13] [14] Particularly, LPA induces vascular smooth muscle cell (SMC) contraction 15 and elevates arterial blood pressure in rats. 16 Local application of LPA causes cerebral vasoconstriction in pigs. 17 Patients with hypertension showed significantly higher plasma LPA level compared with controls. 18, 19 These suggest that LPA and its receptors may be involved in blood pressure regulation and associated with hypertension. 20 Here, we performed a 3-stage population-based genetic association study in Han Chinese to evaluate whether LPARs are associated with EH and if so, how such association interacts with stresses to influence blood pressure in LPAR1-deficient mice.
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Materials and Methods
Animal experiments were performed in accordance with National Institutes of Health guidelines and protocols were approved by the Institutional Animal Care and Use Committee (IACUC) of Peking University (IACUC No.: IMM-Tian XL-04), and all mice were maintained in a specific pathogen-free environment certified by the American Association for Accreditation of Laboratory Animal Care (AAALAC). Detailed description of the Materials and Methods used in this study is available in the online-only Data Supplement.
Results
Characteristics of Populations
Two thousand six hundred thirty patients with EH and 3171 controls of Han Chinese were recruited from 3 geographically independent medical centers in total. The characteristics of these populations are shown in Table 1 . In addition to the prevalence of coronary artery disease and diabetes mellitus, the biochemical parameters were significantly different between case and control groups at each center. Although most of the hypertensive patients were treated with antihypertensive drugs, the SBP and diastolic blood pressure remained higher compared with their counterparts (Table 1) .
Single-Nucleotide Polymorphism Association Test
Twenty-nine single-nucleotide polymorphisms (SNPs) from the LPAR1, LPAR2, LPAR3, LPAR4, LPAR5, and LPAR6 genes and their flanking sequences were first genotyped in population 1 by multiplex ligation-dependent probe amplification. Twenty-eight SNPs were genotyped successfully. The 28 SNPs are shown in Table S5 . The primers used for multiplex ligation-dependent probe amplification and sequencing are listed in Tables S2 and S3 . The consistency between 2 genotyping methods was generally >99%. All SNPs passed the Hardy-Weinberg equilibrium test (Table S5) . In allelic association analysis, 2 SNPs in the LPAR1 gene, rs2766997 (P=0.037) and rs531003 (P=0.006), exhibited positive signals (P<0.05) associated with EH in population 1 in the regression test adjusted risk factors, including sex, age, body mass index, and diabetes mellitus (Table S5) .
Replication Study and Genotypic Association Test
To validate the association in population 1, we genotyped the 2 SNPs, rs531003 and rs2766997, in population 2 and population 3. The SNP rs531003 remained positive (P<0.05) in association with EH, whereas rs2766997 failed to be validated in population 2 and population 3 ( Table 2 ). In a combined analysis, the Bonferroni-corrected P value for rs531003 was 1.09×10 -5 (Table 2) , and the statistical power was 0.91. Genotypic association analysis showed that SNP rs531003 presented significant associations mainly in the dominant and additive genetic models (Table S6) .
Effect of EH Risk Factors on Genetic Association
To understand the interaction between genetic variants and other risk factors, we performed subgroup analysis on rs531003. We found that the association of rs531003 with EH was more significant in female (P=2.68×10 -5 ) and young populations (P=0.001; Table 3 ) compared with their counterparts, respectively. The risk allele was enriched in young female EH patients ( Figure S1 ). The interaction between sex and rs531003 was significant (P=0.030; Table 3 ).
We noticed that the genetic association of rs531003 with EH was influenced by sleep quantity and the P value for the interaction was 0.012 (Table 3) . When having a shortage of sleep (<4 hours per day), those with risk allele (C) rs531003 became susceptible to hypertension (P=4.73×10 -5 ) with the odds ratio of 1.75 (Table 3 ). The power was 0.98 with α=0.05.
Risk Allele C of rs531003 Correlates With Increased Expression of LPAR1
SNP rs531003 is localized in the region downstream from LPAR1 gene. To test the correlation between SNP genotypes and LPAR1 expression, we genotyped 278 healthy individuals. Genotypes GG, CG, and CC were found in 124, 130, and 24 individuals, respectively. Then, we quantified LPAR1 expression in white blood cells using real-time polymerase chain reaction. Results proved that risk allele C was significantly associated with increased expression of LPAR1. The P value for ANOVA was 0.001 and a post hoc Fisher's least significant difference (LSD) test showed that LPAR1 expression varied significantly between individuals of different genotypes (P GG-CG =0.04, P CG-CC =0.01, P GG-CC =2.0×10 -4 ; Figure 1 ).
Null Function of LPAR1 Reduced Blood Pressure and Inhibited Blood Pressure Elevation Caused by Sleep Deprivation and Phenylephrine-Induced Vasoconstriction
To confirm that shortage of sleep affects the contribution of LPAR1 on blood pressure, we measured the blood pressure by a noninvasive tail-cuff method in LPAR1-deficient mice before and after subjected to 24 hours of gentle sleep deprivation (Table  S7 ). The average SBP of the wild-type (WT, n=8) group was 102.2 mm Hg, whereas that of heterozygote group (n=6) and homozygote group (n=5) was 99.0 and 95.0 mm Hg, respectively ( Figure 2A ). The P value for ANOVA was 0.009 and a post hoc LSD test showed that SBPs were significantly different between WT and homozygotes (P WT-homozygotes =0.002; Figure 2A ). Delta SBP was represented as a difference in SBP 24 hours before and after gentle sleep deprivation. The average delta SBP in the WT, heterozygote, and homozygote group was 16.0, 12.1, and 9.3 mm Hg, respectively ( Figure 2B ). The P value for ANOVA was 2.38×10 -4 and a post hoc LSD test showed that Delta SBPs varied significantly between WT, heterozygotes, and homozygotes (P WT-homozygotes =7.3×10 -5 , P WT-heterozygotes =0.005, P heterozygotes-homozygotes =0.05; Figure 2B ).
To evaluate the vascular response of LPAR1-deficient mice to phenylephrine, the aorta rings were obtained. We found that the average constriction forces in WT, heterozygote (LPAR1 BMI indicates body mass index; CAD, coronary artery disease; DM, diabetes mellitus; OR (95% CI), odds ratio with 95% confidence interval; P value, raw P value from logistic regression; and P G×E , raw P value from logistic regression of gene×environment interaction analysis. 
Discussion
In this study, we found that genetic variant of LPAR1 (rs531003) was significantly associated with EH and showed that an elevated expression of LPAR1 which associated with risk allele C of rs531003 increased susceptibility to EH. We demonstrated that LPAR1-deficient mice presented a diminished SBP and response to both phenylephrine-induced vasoconstriction and sleep deprivation-induced blood pressure elevation compared with WT mice. Our findings provide strong evidence that LPAR1 is a novel susceptibility gene for human EH and indicate stresses, such as a shortage of sleep, enhance the susceptibility of those with EH risk allele.
LPA is a small, ubiquitous phospholipid that acts as an extracellular signaling molecule by binding to and activating LPARs. 21 Emerging evidences suggest that LPA-mediated signaling pathways may play a role in regulation of blood pressure. For instance, intravenous injection of LPA elevates arterial blood pressure in rodents 16 and local application causes cerebral vasoconstriction in pigs. 17 Human hypertensive patients have higher levels of LPA 19 and autotaxin (a main producer of serum/plasma LPA). 22 However, it remains unknown whether or not genetic variants of LPA receptors in humans are associated with EH.
Here, we provide evidence that shows LPAR1 is a novel susceptibility gene for human EH and indicates stress, such as shortage of sleep, increases the susceptibility of patients with risk allele to EH. First, we showed that a common genetic variant in LPAR1 gene (rs531003) was associated with EH in 3 geographically independent populations. Second, in subgroup analysis, we found that the risk allele (C) of rs531003 was enriched in young and in female EH sufferers. In addition, we found an enrichment of the C allele in EH patients with a shortage of sleep. In the control group, we observed an association of rs531003 genotype with SBP in healthy controls without coronary artery disease (Table S8) , supporting the association of rs531003 with blood pressure. Finally, we demonstrated that mice lacking the LPAR1 gene presented an attenuated response to sleep deprivation-induced blood pressure elevation and phenylephrine-induced vasoconstriction, dependent on the dosages of LPAR1 gene. These genetic and functional evidences suggest that LPAR1 is an EH susceptibility gene.
Previously, it has been shown that stresses induce the release of epinephrine into the circulation and elevate blood pressure, 5, 23, 24 indicating a psychophysiological link between stress, adrenomedullary activation, and hypertension. 25 We demonstrated that the arteries from LPAR1-deficient mice became less responsive to phenylephrine stimulation in contraction, Two hundred seventy-eight healthy individuals were randomly recruited, and rs531001 was genotyped by direct sequencing. The individuals were divided into GG, CG, and CC groups. The expression level of LPAR1 was quantified by real-time polymerase chain reaction and presented as normalized relative expression, which was correlated with the true amount of LPAR1 transcripts. Data are showed in boxand-whisker plot, with the minimum data, the first quartile, the median, the third quartile, and the maximum data. The average normalized relative expression levels were compared between the GG, CG, and CC group by 1-way ANOVA and post hoc multiple comparisons. LPAR1 indicates lysophosphatidic acid receptor1; and P, P value of post hoc multiple comparisons. Sleep deprivation is a common stress in modern society and has been thought to be an important risk factor for hypertension. 26 But whether shortage of sleep elevates circulatory epinephrine seems controversial. 27, 28 This may imply that the mechanism for sleep deprivation-induced elevation in blood pressure is complicated. In this study, phenylephrine-induced vasoconstriction and sleep deprivation-induced blood pressure elevation were both attenuated in LPAR1-deficient mice, indicating that LPAR1 is involved in these 2 processes through a distinct mechanism.
The role of LPAR1 gene in hypertension induced by stress remains unclear. It is known that epinephrine is elevated in stress condition, such as mental stress, 5 and LPA is elevated in the serum of hypertensive patients. 18, 19 Both are vasoconstrictors and G protein-coupled receptor agonists. Although it remains unknown how LPA and epinephrine influence blood pressure synergistically, a crosstalk has been observed between LPA-LPAR pathway and epinephrine-adrenergic receptor pathway. For example, YAP is involved in LPA-induced gene expression and also regulated by epinephrine. 29 In addition, LPA inhibits epidermal growth factor-induced Stat1 activation, which is also inhibited by epinephrine. 30 LPARs mediate a broad array of functions, such as SMC contraction 15 and arterial blood pressure elevation, in rats 16 and LPAR1 is abundantly expressed in the vasculature. 31 The risk allele (C) found in our study is associated with increased LPAR1 expression. The results from the LPAR1-deficient mouse model showed that it is possible that overexpressed LPAR1 enhances the sensitivity and responses of an individual to stresses, providing a possible explanation of how the genetic variant is linked to stress-induced hypertension.
This study also presents several limitations. First, despite the 3 geographically isolated populations subjected to the study, they are all from Han Chinese. Thus, the association of LPAR1 with hypertension in other ancestries remains to be tested.
To date, several GWAS on hypertension have been reported, providing a comprehensive tool to search for candidate genes for hypertension at a genome level. [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] However, LPAR1 has not been reported by these GWAS. It was probably because the results of GWAS can be affected by several factors, such as population size, stratification, conservative statistic cutoff, and chip density. Unfortunately, the genotyped individuals in original GWAS of Chinese hypertensive populations 38, 39 were relatively small, which may not be sufficient to discover the association of LPAR1 with hypertension when P value cutoff was set as GWAS significance (<10 -7 ). Although some meta-analysis 35, 40, 41 in East Asian increased sample size by combining various experiments, it can be strongly disturbed by the experimental similarity and validity. These disturbances, together with strict P cutoff, may lead to ignorance of those who have mild effects on trait. However, we observed a moderate association in the International Consortium for Blood Pressure Genome-Wide Association Study, 32 indicating a mild effect of LPAR1 in whites (Table S10) .
It seems that candidate gene approach, GWAS, and meta-analysis have its own power and advantages, so one cannot be simply replaced by the others. A combination of genetic and functional studies may provide solid evidence to claim a true candidate gene. Nonetheless, our findings on association of LPAR1 with hypertension need to be validated in other populations in the future.
Then, restricted by the selection criteria in this study, the SNPs that we genotyped do not fully cover the other LPAR genes (Table S9) . Thus, we cannot completely exclude the possibility that the other LPARs may be associated with hypertension. In addition, although we provide the evidence that the risk allele of rs531003 is associated with an upregulated LPAR1 expression, whether it influences the expressions of other genes cannot be excluded.
Finally, telemetry method provides a way to monitor blood pressure continuously in freely moving and conscious animals. Therefore, it can collect more information on changes of blood pressure with time, which cannot be given by the tail-cuff method used in this study.
In summary, we provide evidence that shows LPAR1 is a novel susceptibility gene for human EH and indicates that stress, such as shortage of sleep, increases the susceptibility of patients with risk allele to EH. The underlying mechanism needs to be further investigated.
Perspectives
We demonstrate for the first time that an increased expression of LPAR1 enhances the susceptibility of EH, and indicate LPAR1 may be involved in stress induced blood pressure elevation, through human population genetics and animal models. Our study suggests several possible clinical implications in prediction of EH with the identified genetic variants in LPAR1 and in control of hypertension via suppression of LPAR1. 
Materials and Methods Populations and the Clinical Assessment of Risk Factors
All of the 2630 EH patients in this study were hospitalized patients from three medical centers in north-eastern China (Harbin and Shenyang) and northern China (Beijing). Characteristics of population were showed in Table 1 and the procedures followed were in accordance with institutional guidelines. Clinical definition of EH and risk factors has been previously described 1 . Normotensive subjects (3171 participants) were included from those who had a regular physical exam over the past 5 years in the three centers and met the following criteria: 1) systolic blood pressure (SBP) and diastolic blood pressure (DBP) were never above 140 and 90 mmHg, 2) no family history of hypertension was reported, and 3) one never received antihypertensive treatments. Diabetes mellitus (DM) was diagnosed according to the criteria of the American Diabetes Association (taking hypoglycemic agents, or fasting serum glucose level ≥ 7.0 mmol/L or a 2-hour postprandial glucose level ≥ 11.1 mmol/L in two measurements). Those with fasting serum glucose level in the range of 5.6-7.0 mmol/L or a 2-hour postprandial glucose level in 7.8-11.1 mmol/L were subjected to oral glucose tolerance test for inclusion or exclusion. Clinical definition of coronary artery disease (CAD) has been previously described in detail 2 . Briefly, CAD was defined according to one of the following criteria: existing myocardial infarction; treated with percutaneous coronary intervention (PCI) or coronary artery bypass graft (CABG); more than 50% diameter stenosis of at least one of the three major coronary arteries demonstrated angiographically. Questions of average daily sleep hours were administered through personal interviews before physical exam. According to their sleep quantity, people were separated into three groups (less than 4 hours, 4-7 hours and more than 7 hours). Body mass index (BMI) was measured according to the formula: body weight (kg)/height 2 (m 2 ).
Ethics Statement
A signed consent form was obtained from each participant. The study protocols were approved by the local hospital ethics committees. The study conformed to the principles outlined in the Declaration of Helsinki.
Single-nucleotide polymorphism (SNP) Selection and Genotyping
Based on HapMap (CHB database, HapMap release 24, 2008, November), SNPs were selected based on the following criteria: 1) tagging SNPs based on r 2 ≥ 0.8, 2) functional if possible, and 3) minor allele frequency (MAF) ≥ 5%. Human genomic DNA was isolated from white blood cells using the proteinase K method described previously 3 . Two genotyping methods, direct Sanger sequencing and multiplex ligation-dependent probe amplification (MLPA) were used to avoid the bias caused by a single genotyping method. In brief, 10 ng of genomic DNA from each participant was used to amplify DNA fragments of 150-250 base pair containing the SNPs by PCR with the primers listed in Supplementary Table S2 . After purification by PEG precipitation, the DNA fragment was subjected to direct sequencing on an ABI 3130XL according to the manual description included in the BigDye v3.1 kit. MLPA was according to the description by Schouten 4 . PCR primers and probes used for MLPA are listed in Supplementary Table S3 . To validate the genotypes produced by MLPA, for each SNP, we randomly selected 150 individuals from cases and controls respectively and sequenced the target regions. The primers used for sequencing are listed in Supplementary Table S2 . Sequences of fluorescent universal primers were 5'-FAM-GGATA CGACT CACTA TAGGT -3' and 5'-Hex-GCGGA TAACA AGTTC ACACT-3'.
Expression Quantitative Trait Loci (eQTL) Analysis
We recruited 278 healthy individuals successively from medical center in Beijing. Both DNA and RNA were isolated from these samples. Genotype of rs531003 in 278 healthy individuals was detected by direct Sanger sequencing. Total RNA was isolated from white blood cells and purified according to the TRIzol reagent (Invitrogen) method. The expression level of LPAR1 was quantified by real-time PCR and presented as normalized relative expression. 5 μg of RNA were used for reverse transcription in a 20 μL reaction system containing 1× PCR buffer, 0.5 mM each dNTP, 0.5 μM random primer, 20 U of RNasin, and 50 U M-MLV. The reaction was carried out at 42
• C for 40 min and terminated by heat at 98 • C for 5 min. Subsequently, PCR was performed in a 20 μL system consisting of 1× PCR buffer, 0.2 mM each dNTP, and 0.2 mM each primer. Primers are described in Supplementary Table S4 .
LPAR1-deficient
Mice LPAR1-deficient mice on a BALB/c background and genotyping methods have been previously described [5] [6] [7] . All experiments were carried out in accordance with National Institutes of Health guidelines and protocols were approved by the Institutional Animal Care and Use Committee (IACUC) of Peking University (IACUC No.: IMM-Tian XL-04), and all mice were maintained in a specific pathogen-free (SPF) environment certified by the American Association for Accreditation of Laboratory Animal Care (AAALAC). In total, 19 female mice were used (detailed information see Supplementary Table S7 ). Male mice were not subjected to the study since mice were transferred from prof. Jerold Chun's lab in the U.S.A. to China, we did not obtain sufficient number of male homozygotes.
Sleep Deprivation Procedure
For all experiments, gentle sleep deprivation (GSD) started at light onset (corresponding to zeitgeber time zero) and lasted for 24 hours. Mice were moved to an adjacent room and continuously observed. GSD was performed according to the method previously described 8, 9 . Using this method, the animals were kept awake by providing new nesting material or new objects into their home cage when they adopted a sleeping posture and immobility. Mice were not handled, touched, or stimulated by cage moving. They were not disturbed when they were drinking or eating. The blood pressure of mice was measured using a non-invasive tail-cuff blood pressure measure system (BP-98A, Softron Biotechnology, China) in the awake mice before and after the GSD. Mice holder was placed on an electric heater (TMS-202, Softron Biotechnology, China, the setting temperature is 37℃) to keep the body temperature of mice. All mice were acclimated to the measurement procedure for four days. The measurement was performed on the fifth day. Blood pressure of every mouse was finished when we get at least 15 successively stable reads.
Vasoconstriction Studies
Aortic vasoconstriction was measured using isometric tension 10 . The thoracic aorta was quickly removed and cut into 2 mm in length and placed in an organ bath containing 5 ml HEPES solution maintained at 37 °C. The rings were connected to a force transducer (DMT-410, Danish Myo Technology A/S Inc, Denmark) to measure isometric tension. Increasing concentrations of phenylephrine (an adrenomimetic drug, 10
-5 mol/L, Sigma Aldrich) were added to the chamber to obtain cumulative concentration-response curves of vasoconstriction.
Statistical Analysis
Data were showed as mean and standard deviation of the mean (SD). Hardy-Weinberg equilibrium test for all SNPs was calculated using the Chi-square test. Differences in allele and genotype distribution between EH patients and controls were analyzed using binary logistic regression under various genetic models. Multiple comparison correction was calculated using Bonferroni method. The two-tailed P values, odds ratios (OR), and 95% confidence intervals (95% CI) are presented for all association tests. One-way ANOVA followed by a post-hoc LSD test was used to compare normalized expression of LPAR1 among three genotype groups (CC, CG and GG) in human, and to compare vasoconstriction and blood pressure among three groups (LPAR1 Minor allele frequency in the young female case group was higher than that in the old female case group and female control group. The minor allele frequencies were compared between the young female case group, the old female case group, and the female control group by one-way ANOVA and post hoc multiple comparisons. P, P value of post hoc multiple comparisons. MAF, minor allele frequency.
Supplementary Figure S2 . LPAR1 expression level in aorta of LPAR1-deficient mice.
Total RNA was isolated from aorta of LPAR1-deficient mice and purified according to the TRIzol reagent (Invitrogen) method. The expression level of LPAR1 was quantified by real-time PCR and presented as normalized relative expression, which was correlated with the true amount of LPAR1 transcripts. WT, wild type mice (n=8). LPAR1+/-, LPAR1-deficient mice heterozygotes (n=6). LPAR1-/-, LPAR1-deficient mice homozygotes (n=5).
